Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles

Diana L. Castillo-Carranza, Urmi Sengupta, Marcos J. Guerrero-Muñoz, Cristian A. Lasagna-Reeves, Julia E. Gerson, Gurpreet Singh, D. Mark Estes, Alan Barrett, Kelly Dineley, George R. Jackson, Rakez Kayed

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Recent findings suggest that tau oligomers, which form before neurofibrillary tangles (NFTs), are the true neurotoxic tau entities in neurodegenerative tauopathies, including Alzheimer's disease (AD). Studies in animal models of tauopathy suggest that tau oligomers play a key role in eliciting behavioral and cognitive impairments. Here, we used a novel tau oligomer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau. A single dose of TOMA administered either intravenously or intracerebroventricularly was sufficient to reverse both locomotor and memory deficits in a mouse model of tauopathy for 60 d, coincident with rapid reduction of tau oligomers but not phosphorylated NFTs or monomeric tau. Our data demonstrate that antibody protection is mediated by extracellular and rapid peripheral clearance. These findings provide the first direct evidence in support of a critical role for tau oligomers in disease progression and validate tau oligomers as a target for the treatment of AD and other neurodegenerative tauopathies.

Original languageEnglish (US)
Pages (from-to)4260-4272
Number of pages13
JournalJournal of Neuroscience
Volume34
Issue number12
DOIs
StatePublished - 2014

Fingerprint

Tauopathies
Neurofibrillary Tangles
Passive Immunization
Monoclonal Antibodies
Phenotype
Alzheimer Disease
Memory Disorders
Disease Progression
Animal Models
Antibodies

Keywords

  • Alzheimer's disease
  • Immunotherapy
  • Tau oligomers
  • Tauopathies

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. / Castillo-Carranza, Diana L.; Sengupta, Urmi; Guerrero-Muñoz, Marcos J.; Lasagna-Reeves, Cristian A.; Gerson, Julia E.; Singh, Gurpreet; Mark Estes, D.; Barrett, Alan; Dineley, Kelly; Jackson, George R.; Kayed, Rakez.

In: Journal of Neuroscience, Vol. 34, No. 12, 2014, p. 4260-4272.

Research output: Contribution to journalArticle

Castillo-Carranza, DL, Sengupta, U, Guerrero-Muñoz, MJ, Lasagna-Reeves, CA, Gerson, JE, Singh, G, Mark Estes, D, Barrett, A, Dineley, K, Jackson, GR & Kayed, R 2014, 'Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles', Journal of Neuroscience, vol. 34, no. 12, pp. 4260-4272. https://doi.org/10.1523/JNEUROSCI.3192-13.2014
Castillo-Carranza, Diana L. ; Sengupta, Urmi ; Guerrero-Muñoz, Marcos J. ; Lasagna-Reeves, Cristian A. ; Gerson, Julia E. ; Singh, Gurpreet ; Mark Estes, D. ; Barrett, Alan ; Dineley, Kelly ; Jackson, George R. ; Kayed, Rakez. / Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. In: Journal of Neuroscience. 2014 ; Vol. 34, No. 12. pp. 4260-4272.
@article{e168e07284794eda96d726a12519d715,
title = "Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles",
abstract = "Recent findings suggest that tau oligomers, which form before neurofibrillary tangles (NFTs), are the true neurotoxic tau entities in neurodegenerative tauopathies, including Alzheimer's disease (AD). Studies in animal models of tauopathy suggest that tau oligomers play a key role in eliciting behavioral and cognitive impairments. Here, we used a novel tau oligomer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau. A single dose of TOMA administered either intravenously or intracerebroventricularly was sufficient to reverse both locomotor and memory deficits in a mouse model of tauopathy for 60 d, coincident with rapid reduction of tau oligomers but not phosphorylated NFTs or monomeric tau. Our data demonstrate that antibody protection is mediated by extracellular and rapid peripheral clearance. These findings provide the first direct evidence in support of a critical role for tau oligomers in disease progression and validate tau oligomers as a target for the treatment of AD and other neurodegenerative tauopathies.",
keywords = "Alzheimer's disease, Immunotherapy, Tau oligomers, Tauopathies",
author = "Castillo-Carranza, {Diana L.} and Urmi Sengupta and Guerrero-Mu{\~n}oz, {Marcos J.} and Lasagna-Reeves, {Cristian A.} and Gerson, {Julia E.} and Gurpreet Singh and {Mark Estes}, D. and Alan Barrett and Kelly Dineley and Jackson, {George R.} and Rakez Kayed",
year = "2014",
doi = "10.1523/JNEUROSCI.3192-13.2014",
language = "English (US)",
volume = "34",
pages = "4260--4272",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "12",

}

TY - JOUR

T1 - Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles

AU - Castillo-Carranza, Diana L.

AU - Sengupta, Urmi

AU - Guerrero-Muñoz, Marcos J.

AU - Lasagna-Reeves, Cristian A.

AU - Gerson, Julia E.

AU - Singh, Gurpreet

AU - Mark Estes, D.

AU - Barrett, Alan

AU - Dineley, Kelly

AU - Jackson, George R.

AU - Kayed, Rakez

PY - 2014

Y1 - 2014

N2 - Recent findings suggest that tau oligomers, which form before neurofibrillary tangles (NFTs), are the true neurotoxic tau entities in neurodegenerative tauopathies, including Alzheimer's disease (AD). Studies in animal models of tauopathy suggest that tau oligomers play a key role in eliciting behavioral and cognitive impairments. Here, we used a novel tau oligomer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau. A single dose of TOMA administered either intravenously or intracerebroventricularly was sufficient to reverse both locomotor and memory deficits in a mouse model of tauopathy for 60 d, coincident with rapid reduction of tau oligomers but not phosphorylated NFTs or monomeric tau. Our data demonstrate that antibody protection is mediated by extracellular and rapid peripheral clearance. These findings provide the first direct evidence in support of a critical role for tau oligomers in disease progression and validate tau oligomers as a target for the treatment of AD and other neurodegenerative tauopathies.

AB - Recent findings suggest that tau oligomers, which form before neurofibrillary tangles (NFTs), are the true neurotoxic tau entities in neurodegenerative tauopathies, including Alzheimer's disease (AD). Studies in animal models of tauopathy suggest that tau oligomers play a key role in eliciting behavioral and cognitive impairments. Here, we used a novel tau oligomer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau. A single dose of TOMA administered either intravenously or intracerebroventricularly was sufficient to reverse both locomotor and memory deficits in a mouse model of tauopathy for 60 d, coincident with rapid reduction of tau oligomers but not phosphorylated NFTs or monomeric tau. Our data demonstrate that antibody protection is mediated by extracellular and rapid peripheral clearance. These findings provide the first direct evidence in support of a critical role for tau oligomers in disease progression and validate tau oligomers as a target for the treatment of AD and other neurodegenerative tauopathies.

KW - Alzheimer's disease

KW - Immunotherapy

KW - Tau oligomers

KW - Tauopathies

UR - http://www.scopus.com/inward/record.url?scp=84896269359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896269359&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.3192-13.2014

DO - 10.1523/JNEUROSCI.3192-13.2014

M3 - Article

C2 - 24647946

AN - SCOPUS:84896269359

VL - 34

SP - 4260

EP - 4272

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 12

ER -